Literature DB >> 16680578

A role for substance P in cancer promotion and progression: a mechanism to counteract intracellular death signals following oncogene activation or DNA damage.

F Esteban1, M Muñoz, M A González-Moles, M Rosso.   

Abstract

In the present review we discuss a central role for substance P (SP) in carcinogenesis. We suggest that one mechanism to induce mitogenesis of tumor cells is the activation of neurokinin-1 receptor (NK1R) through SP, linking cancer promotion and progression to a neurokinin-mediated environment. After reviewing the role of both SP and its receptor NK1R in normal and neoplastic cells we propose the use of neurokinin-1 receptor antagonists as a novel and promising approach for treating patients with cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16680578     DOI: 10.1007/s10555-006-8161-9

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  29 in total

Review 1.  Tachykinin peptide, substance P, and its receptor NK-1R play an important role in alimentary tract mucosal inflammation during cytotoxic therapy.

Authors:  P S Satheeshkumar; Minu P Mohan
Journal:  Dig Dis Sci       Date:  2014-07-01       Impact factor: 3.199

Review 2.  Involvement of substance P and the NK-1 receptor in pancreatic cancer.

Authors:  Miguel Muñoz; Rafael Coveñas
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

3.  Immunohistochemical expression of SP-NK-1R-EGFR pathway and VDR in colonic inflammation and neoplasia.

Authors:  Raymond A Isidro; Myrella L Cruz; Angel A Isidro; Axel Baez; Axel Arroyo; William A González-Marqués; Carmen González-Keelan; Esther A Torres; Caroline B Appleyard
Journal:  World J Gastroenterol       Date:  2015-02-14       Impact factor: 5.742

4.  The NK-1 receptor is expressed in human leukemia and is involved in the antitumor action of aprepitant and other NK-1 receptor antagonists on acute lymphoblastic leukemia cell lines.

Authors:  Miguel Muñoz; Ana González-Ortega; Rafael Coveñas
Journal:  Invest New Drugs       Date:  2010-12-01       Impact factor: 3.850

5.  Truncated neurokinin-1 receptor is an ubiquitous antitumor target in hepatoblastoma, and its expression is independent of tumor biology and stage.

Authors:  Agnès Garnier; Matthias Ilmer; Kristina Becker; Beate Häberle; Dietrich VON Schweinitz; Roland Kappler; Michael Berger
Journal:  Oncol Lett       Date:  2015-11-20       Impact factor: 2.967

Review 6.  The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs.

Authors:  Miguel Munoz; Rafael Covenas; Francisco Esteban; Maximino Redondo
Journal:  J Biosci       Date:  2015-06       Impact factor: 1.826

7.  Neurokinin 1 receptor mediates membrane blebbing in HEK293 cells through a Rho/Rho-associated coiled-coil kinase-dependent mechanism.

Authors:  John Meshki; Steven D Douglas; Jian-Ping Lai; Lynnae Schwartz; Laurie E Kilpatrick; Florin Tuluc
Journal:  J Biol Chem       Date:  2009-01-28       Impact factor: 5.157

8.  The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug.

Authors:  Miguel Muñoz; Marisa Rosso
Journal:  Invest New Drugs       Date:  2009-01-17       Impact factor: 3.850

9.  SR140333 counteracts NK-1 mediated cell proliferation in human breast cancer cell line T47D.

Authors:  Wei-Qing Huang; Ji-Gang Wang; Lei Chen; Hong-Jun Wei; Hua Chen
Journal:  J Exp Clin Cancer Res       Date:  2010-05-24

10.  Neurotransmitter substance P mediates pancreatic cancer perineural invasion via NK-1R in cancer cells.

Authors:  Xuqi Li; Guodong Ma; Qingyong Ma; Wei Li; Jiangbo Liu; Liang Han; Wanxing Duan; Qinhong Xu; Han Liu; Zheng Wang; Qing Sun; Fengfei Wang; Erxi Wu
Journal:  Mol Cancer Res       Date:  2013-01-23       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.